RxSight Q2 Sales $34.887M Beat $32.283M Estimate
Portfolio Pulse from Benzinga Newsdesk
RxSight (NASDAQ:RXST) reported Q2 sales of $34.887 million, surpassing the analyst consensus estimate of $32.283 million by 8.07%. This marks a 67.65% increase over the same period last year.
August 05, 2024 | 8:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RxSight reported Q2 sales of $34.887 million, beating the analyst consensus estimate of $32.283 million by 8.07%. This represents a 67.65% increase over the same period last year.
The significant beat on sales estimates and the substantial year-over-year growth are likely to positively impact RxSight's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100